MK-8353是一个强效的、口服活性的 ERK1/2 抑制剂,是一个抗癌药物候选物,正在由 Schering-Plough 开发,已在各种前临床癌症模型中显示出与 SCH772984 相当的效能。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | ERK ↓ ↑ | ERK1 ↓ ↑ | ERK2 ↓ ↑ | ERK5 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DEL-22379 |
+
ERK, IC50: 0.5 μM |
+
ERK, IC50: 0.5 μM |
98% | ||||||||||||||||
Pluripotin |
++
ERK1, Kd: 98 nM |
RasGAP | 98+% | ||||||||||||||||
FR 180204 |
+
ERK1, Ki: 0.31 μM |
++
ERK2, Ki: 0.14 μM |
98% | ||||||||||||||||
Ravoxertinib |
+++
ERK1, IC50: 1.1 nM |
++++
ERK2, IC50: 0.3 nM |
99%+ | ||||||||||||||||
SCH772984 |
+++
ERK1, IC50: 4 nM |
++++
ERK2, IC50: 1 nM |
99%+ | ||||||||||||||||
Temuterkib |
+++
ERK1, IC50: 5 nM |
+++
ERK2, IC50: 5 nM |
99%+ | ||||||||||||||||
VX-11e |
+++
ERK2, Ki: <2 nM |
99%+ | |||||||||||||||||
Ulixertinib |
++++
ERK2, IC50: <0.3 nM |
99%+ | |||||||||||||||||
XMD17-109 |
++
ERK5, IC50: 162 nM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | MK-8353 a highly potent and selective ERK1/2 inhibitor with IC50 values of 20/7nM, possessing good oral bioavailability and anti-tumor efficacy. MK-8353 exhibited anti-proliferative effect on A2058, HT-29 and Colo-205 cells with IC50 values of 371, 51 and 23nM. Oral administration of MK-8353 for 28 days achieved a tumor growth inhibition by 88% at dose of 40mg/kg, BID, and tumor regression by 40% at dose of 60mg/kg, BID, in a Colo-205 human colon xenograft model. MK-8353 caused a dose-proportional decrease in the pERK1/2, and ribosomal S6 kinase (pRSK) proteins, with complete suppression of pERK1 and pERK2 observed at 30 nM MK-8353 in A2058 cells post 24h. |
作用机制 | MK-8353 is an indazole-pyrrolidine derivative and it can form a complex with ERK, which leads to the inability of MEK to catalyze the phosphorylation of the ERK–MK-8353 complex.[3] |
Dose | Mice: 10 mg/kg[1] (i.v.); 30 mg/kg[1] (p.o.) Rat: 3 mg/kg[1] (i.v.); 30 mg/kg[1] (p.o.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Administration | i.v., p.o. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacokinetics |
|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01358331 | Tumor, Solid | Phase 1 | Terminated | - | - |
NCT03745989 | Solid Tumors | Phase 1 | Not yet recruiting | May 6, 2022 | - |
NCT02972034 | Neoplasms Col... 展开 >>orectal Cancer 收起 << | Phase 1 | Recruiting | October 29, 2021 | United States, Michigan ... 展开 >> Call for Information (Investigational Site 0002) Recruiting Grand Rapids, Michigan, United States, 49546 United States, Tennessee Call for Information (Investigational Site 0001) Recruiting Nashville, Tennessee, United States, 37203 Canada, Quebec Merck Canada Recruiting Kirkland, Quebec, Canada, H9H 4M7 Contact: Medical Information Centre Centre d'information medicale Merck Canada Inc. 514-428-8600 / 1-800-567-2594 收起 << |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.45mL 0.29mL 0.14mL |
7.23mL 1.45mL 0.72mL |
14.45mL 2.89mL 1.45mL |
CAS号 | 1184173-73-6 |
分子式 | C37H41N9O3S |
分子量 | 691.845 |
别名 | SCH900353 |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry,2-8°C |
溶解方案 |
DMSO: 105 mg/mL(151.77 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 |